secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001140361-23-022852
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed Q1 revenue up 23% to $65.2M; net loss widens to $159.8M; pipeline on track
--------------------------------------------------------------------------------

- ARIKAYCE global revenue $65.2M, up 23% YoY; U.S. net sales $49.1M, Japan $13.2M.
- Net loss $159.8M ($1.17/share) vs $94.6M ($0.80) in Q1 2022; R&D spend rose to $127.9M.
- Cash and securities $999M at March 31, 2023, down from $1.15B at Dec 31, 2022.
- Phase 3 ASPEN enrollment completed (1,700+ patients); topline data expected Q2 2024.
- Reaffirmed FY2023 ARIKAYCE revenue guidance $285M-$300M; appointed Makoto Nakamura GM Japan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036123022852/0001140361-23-022852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036123022852/brhc20052467_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-022852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer